The stock is in a sustained uptrend over the past year, evidenced by a 1-year price change of +15.17%, but is currently experiencing a significant pullback from its highs. As of the latest close at $814.02, the stock is trading at approximately 81% of its 52-week range, positioned between the 52-week low of $637 and the high of $999, indicating it has retreated meaningfully from its peak but remains well above its annual low. This positioning suggests the momentum from the prior uptrend has stalled, and the stock is now testing key support levels after a notable decline from its February highs near $990. Recent momentum has turned sharply negative, with the stock down -6.68% over the past month and -2.07% over the past three months, a stark reversal from the positive 1-year trend. This divergence signals a potential consolidation or correction phase, with the stock showing significant relative weakness compared to the broader market, as indicated by a -16.66 relative strength figure over one month. Key technical support is anchored at the 52-week low of $637, while immediate resistance lies at the recent highs around $990. A breakdown below the current level could target lower support zones, while a recovery above the $950-$990 resistance band would be needed to reinstate the bullish trend. The stock's beta of 0.423 indicates it is significantly less volatile than the broader market, which has implications for risk-adjusted positioning, though the recent drawdown of -18.25% highlights that even low-beta stocks can experience pronounced corrections.

McKesson's revenue trajectory shows consistent growth, with the most recent quarterly revenue reaching $106.16 billion, representing a solid 11.4% year-over-year increase. This growth has been accelerating from prior quarters, as evidenced by sequential revenue increases from $97.83 billion in Q1 to $106.16 billion in Q3 of the current fiscal year, driven primarily by its massive North American Pharmaceutical Segment, which contributed $88.32 billion. The company is profitable, reporting net income of $1.19 billion for the latest quarter, translating to a net margin of 1.12%. However, gross margins remain characteristically thin for a distribution business at 3.47%, though operating margins have shown stability around 1.5%, indicating effective cost control within its low-margin model. The balance sheet and cash flow position is strong, with the company generating robust free cash flow, evidenced by a trailing twelve-month FCF of $10.10 billion. The current ratio of 0.90 suggests adequate short-term liquidity, though the negative debt-to-equity ratio of -3.56 is an accounting artifact typically seen in companies with significant retained earnings or share buybacks reducing equity, and the Return on Equity of -158.87% is similarly distorted by this equity structure, while Return on Assets of 4.33% is a more meaningful measure of operational efficiency.